试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-31
Vascular Dysfunction in Black Individuals: Roles of Nitric Oxide and Endothelin-1
编号:NCT04770155登记状态:提前终止企业 / 申办者:University of Mississippi Medical Center
药物 / 成分:Dietary Nitrates 400 mg、L-citrulline 3 g、Sildenafil 100 mg、Bosentan 125 mg
登记的停止原因(原文):Despite significant effort, we were unable to obtain the supply of drugs and supplements needed for the various arms of this Clinical Trial.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-30
A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer
编号:NCT01849874登记状态:提前终止企业 / 申办者:Pfizer
药物 / 成分:MEK162, MEK inhibitor; oral、Physician's choice chemotherapy
登记的停止原因(原文):Per recommendation of the DMC, enrollment into the study was discontinued in April 2016 after the planned interim efficacy analysis showed the hazard ratio for PFS crossed the predefined futility boundary.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-30
Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma
编号:NCT02425306登记状态:提前终止企业 / 申办者:Craig L Slingluff, Jr
药物 / 成分:6MHP、Montanide ISA-51、polyICLC、Cyclophosphamide
登记的停止原因(原文):Slow accrual to part 2 of the study. Accrual to part 1 is complete.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-30
Labor Induction With Double Balloon Device, Oral Misoprostol and Concomitant Use of Both
编号:NCT03866772登记状态:提前终止企业 / 申办者:Bnai Zion Medical Center
药物 / 成分:Misoprostol Oral Tablet、double balloon device for cervical ripening
登记的停止原因(原文):RECRUTIMENT DIFICULTIES
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-30
Penn Microbiome Therapy (PMT) for Severe-Clostridium Difficile Infection (CDI)
编号:NCT03970200登记状态:提前终止企业 / 申办者:University of Pennsylvania
药物 / 成分:Penn Microbiome Therapy - 001、Penn Microbiome Therapy - 002、Penn Microbiome Therapy - 003、Antibiotics
登记的停止原因(原文):Administrative reasons.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-30
A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome
编号:NCT03992196登记状态:提前终止企业 / 申办者:UCB Biopharma SRL
药物 / 成分:Rotigotine 1 mg/24 h、Rotigotine 2 mg/24 h、Rotigotine 3 mg/24 h
登记的停止原因(原文):Sponsor decision; Not a safety decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-30
Losartan to Improve Hip Microfracture
编号:NCT04212650登记状态:提前终止企业 / 申办者:Steadman Philippon Research Institute
药物 / 成分:Losartan、Placebo
登记的停止原因(原文):redesigned trial using another placebo controlled drug
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-30
Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
编号:NCT04300140登记状态:提前终止企业 / 申办者:Aravive, Inc.
药物 / 成分:Batiraxcept、Cabozantinib (Cabo)、Nivolumab
登记的停止原因(原文):Due to business reasons
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-30
Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer
编号:NCT04729608登记状态:提前终止企业 / 申办者:Aravive, Inc.
药物 / 成分:Batiraxcept、Paclitaxel、Placebo
登记的停止原因(原文):There were no significant differences in median PFS between batiraxcept + paclitaxel or paclitaxel alone arms. There was no detriment to overall survival. No new safety signals were identified.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-30
Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma
编号:NCT04983407登记状态:提前终止企业 / 申办者:Aravive, Inc.
药物 / 成分:batiraxcept、Nab paclitaxel、Gemcitabine
登记的停止原因(原文):Due to business reasons
查看官方原始记录 ↗